Two Sigma Advisers LP Has $103.75 Million Stock Holdings in Incyte Co. (NASDAQ:INCY)

Two Sigma Advisers LP lifted its position in shares of Incyte Co. (NASDAQ:INCY) by 1.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 997,882 shares of the biopharmaceutical company’s stock after purchasing an additional 9,800 shares during the period. Two Sigma Advisers LP owned 0.46% of Incyte worth $103,750,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in INCY. Evoke Wealth LLC grew its stake in Incyte by 143.0% in the 2nd quarter. Evoke Wealth LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 226 shares during the last quarter. Bessemer Group Inc. lifted its stake in Incyte by 248.5% in the 2nd quarter. Bessemer Group Inc. now owns 460 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 328 shares during the last quarter. Ellevest Inc. lifted its stake in Incyte by 97.5% in the 2nd quarter. Ellevest Inc. now owns 547 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 270 shares during the last quarter. Harbor Investment Advisory LLC lifted its stake in Incyte by 27.1% in the 1st quarter. Harbor Investment Advisory LLC now owns 868 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 185 shares during the last quarter. Finally, CSat Investment Advisory L.P. lifted its stake in Incyte by 55.3% in the 1st quarter. CSat Investment Advisory L.P. now owns 1,292 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 460 shares during the last quarter. Institutional investors own 93.35% of the company’s stock.

Several equities analysts recently commented on INCY shares. JPMorgan Chase & Co. reissued a “hold” rating and issued a $99.00 price objective on shares of Incyte in a research note on Tuesday, July 28th. Credit Suisse Group decreased their price target on shares of Incyte from $100.00 to $97.00 and set a “neutral” rating for the company in a research report on Thursday, August 6th. Morgan Stanley upped their price target on shares of Incyte from $95.00 to $100.00 and gave the company an “equal weight” rating in a research report on Thursday, August 6th. Royal Bank of Canada upped their price target on shares of Incyte from $91.00 to $92.00 and gave the company a “sector perform” rating in a research report on Monday, August 3rd. Finally, Mizuho initiated coverage on shares of Incyte in a research report on Tuesday, August 4th. They set a “hold” rating and a $95.00 price objective for the company. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and thirteen have issued a buy rating to the stock. Incyte presently has a consensus rating of “Hold” and an average price target of $101.86.

In related news, EVP Steven H. Stein sold 610 shares of the stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $108.56, for a total value of $66,221.60. Following the completion of the sale, the executive vice president now directly owns 104,131 shares of the company’s stock, valued at approximately $11,304,461.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Herve Hoppenot sold 124,148 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $102.91, for a total transaction of $12,776,070.68. Following the completion of the sale, the chief executive officer now directly owns 245,250 shares of the company’s stock, valued at $25,238,677.50. The disclosure for this sale can be found here. Insiders sold a total of 252,368 shares of company stock worth $26,711,586 in the last quarter. Company insiders own 16.10% of the company’s stock.

NASDAQ:INCY traded down $1.49 during mid-day trading on Wednesday, hitting $89.94. 1,059,033 shares of the stock traded hands, compared to its average volume of 1,649,281. The business’s 50-day moving average price is $94.56 and its 200 day moving average price is $93.02. The company has a market cap of $19.67 billion, a PE ratio of -98.84 and a beta of 1.07. Incyte Co. has a 12-month low of $62.48 and a 12-month high of $110.36. The company has a quick ratio of 3.70, a current ratio of 3.73 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.36. Incyte had a negative net margin of 8.00% and a negative return on equity of 8.06%. The business had revenue of $688.00 million during the quarter, compared to analyst estimates of $617.55 million. During the same period in the previous year, the business posted $0.75 earnings per share. Incyte’s revenue for the quarter was up 29.8% on a year-over-year basis. Analysts anticipate that Incyte Co. will post -1.12 earnings per share for the current fiscal year.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Read More: Diversification For Individual Investors

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.